Safety and immune response kinetics of grad-cov2 vaccine: phase 1 clinical trial results

HIGHLIGHTS

• who: Chiara Agrati from the (UNIVERSITY) have published the research: Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results, in the Journal: (JOURNAL) of December/16,/2021
• what: The authors report on the complete clinical and immunological follow-up from the phase 1 trial of GRAd-COV2, a COVID-19 vaccine candidate based on a gorilla adenovirus. The authors show that a single administration of GRAd-COV2 at peak (w4-8) after vaccination induces anti-Spike and anti-RBD IgG concentrations (geometric mean) in the range of 70-180 BAU . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.